Four Analysts Raised Their Pfizer Targets in One Week Without an Upgrade. Here’s Where the Stock Could Go By 2030
Four Analysts Raised Their Pfizer Targets in One Week Without an Upgrade. Here’s Where the Stock Could Go By 2030 TIKR.com
Covered in this story
What has happened since
- Pfizer is up 0.4% since this was published, 2 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Bank of America’s $29 target on $PFE is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Bank of America’s track record →Tracked from this story
Cantor Fitzgerald’s $28 target on $PFE is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
Cantor Fitzgerald’s track record →Analyst targets on Pfizer
- JPMorgan: $28.3 → $30 by Oct 2027 · Neutral via The Globe and Mail
- Scotiabank: $27.5 → $33 by Oct 2027 · Sector Outperform via GuruFocus
- BMO Capital Markets: $27.3 → $30 by Aug 2027 · Buy via 富途牛牛
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 51 stories mentioning Pfizer, the earliest published 18 Jun 2026.
Summary aggregated from TIKR.com's public RSS feed. The full reporting belongs to TIKR.com — please read it on their site.